
<u>Arman Oruc Speaking at KPMG's 2022</u> <u>Global Life Sciences Summit</u>



Goodwin Antitrust partner, <u>Arman Oruc</u> will be speaking on a timely panel "Dealing in an era of fast evolving innovation: Deals, M&A, and Alliances," at the KPMG 2022 Global Life Sciences Summit this Wednesday, May 18 at 9AM ET. To attend, please register here: <u>https://bit.ly/39jhViE.</u>

<u>Antitrust + Competition Life Sciences</u> <u>Quarterly Update Q1 2022</u>



Despite the aggressive rhetoric, the change in the leadership

and composition at the U.S. Federal Trade Commission (FTC) did not result in more enforcement in 2021. As the calendar turned to 2022, the FTC seems to be stepping up its enforcement track record in the life sciences sector. Antitrust + Competition lawyers <u>Arman Oruc</u>, <u>Andrew Lacy</u>, <u>Sarah</u> <u>Jordan</u> and <u>Elliot Silver</u> discuss how the changes at the FTC have affected life sciences companies in the <u>Antitrust + Competition Life Sciences Quarterly Update</u>.

<u>Biden Executive Order Calls for Heightened</u> <u>Antitrust Scrutiny</u>



On July 9, 2021, President Joe Biden announced a broad executive order (the "Order"). The Order is intended to boost what it characterizes as stagnant competition across the U.S. economy. The Order encourages federal antitrust agencies to "fairly and vigorously" enforce antitrust laws, encourages antitrust and other agencies to focus on perceived competition problems in key industries, and "reaffirms" the authority of the U.S. antitrust agencies to challenge previously consummated transactions. This sweeping Order is likely to launch a series of policy reevaluations and new rulemakings across a multitude of federal agencies.

Read the <u>client alert</u>.